Susquehanna International Group, LLP Eq Rx, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.66 - $2.31 $105,856 - $147,306	-63,769 Reduced 45.66%	75,885 $168,000
Q2 2023 Aug 11, 2023	SELL	$1.61 - $1.96 $404,435 - $492,355	-251,202 Reduced 64.27%	139,654 $259,000
Q1 2023 May 16, 2023	BUY	$1.8 - $2.83 $465,291 - $731,540	258,495 Added 195.3%	390,856 $758,000
Q4 2022 Feb 14, 2023	SELL	$2.05 - $5.5 $281,803 - $756,057	-137,465 Reduced 50.95%	132,361 $325,000
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $215,680 - $1.37 Million	229,447 Added 568.23%	269,826 $1.34 Million
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.69 $250,739 - $445,845	-78,356 Reduced 65.99%	40,379 $190,000
Q1 2022 May 16, 2022	BUY	$2.8 - $7.39 $332,458 - $877,451	118,735 New	118,735 $490,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.